Bipolar Medication During Pregnancy
For women with bipolar disorder during pregnancy, lithium and lamotrigine are the preferred first-line mood stabilizers, while valproate and carbamazepine must be avoided due to high teratogenic risk; atypical antipsychotics (particularly quetiapine, olanzapine, and lurasidone) serve as effective alternatives, and continuing treatment is generally safer than discontinuation given the extremely high postpartum relapse risk.
Primary Treatment Recommendations
First-Line Options
Lithium remains the gold standard despite historical concerns 1, 2. Early reports from the 1970s suggested cardiac malformations (Ebstein's anomaly), but recent case-control and cohort studies demonstrate this risk is substantially lower than previously believed 3. The absolute risk of cardiac defects is small, and lithium can be safely used during the second and third trimesters 4. However, maintaining therapeutic levels requires careful monitoring as renal clearance increases during pregnancy 3.
Lamotrigine has the most favorable safety profile among antiepileptics 1, 4. Studies show no increased risk of major congenital malformations 3. During pregnancy, recurrence rates were 41.2% (lower than untreated patients), and postpartum recurrence was only 7.9% 2. Lamotrigine is also safe during lactation 4.
Atypical antipsychotics are increasingly recognized as safe and effective options:
- Quetiapine, olanzapine, and lurasidone show favorable safety profiles 5, 6
- No statistically significant association with congenital malformations as a class 3
- Olanzapine showed 11.7% postpartum recurrence rate 2
- Women treated with these agents had significantly lower rates of premature delivery and low birth weight compared to untreated patients 5
Medications to Absolutely Avoid
Valproate is contraindicated in women of childbearing potential 1, 4. It causes:
- Neural tube defects
- Craniofacial, cardiac, genital, and musculoskeletal abnormalities
- Developmental delay and lower IQ in children
- Higher risk of autism spectrum disorder 4
- 70.6% postpartum recurrence rate when used (highest among all agents) 2
Carbamazepine is similarly contraindicated in the first trimester due to major congenital malformation risk 4, 3.
Treatment Algorithm
For Women Planning Pregnancy:
- If currently on valproate or carbamazepine: Switch to lithium, lamotrigine, or atypical antipsychotic immediately
- If stable on lithium or lamotrigine: Continue through pregnancy with dose adjustments
- If on atypical antipsychotic: Continue current regimen
During Pregnancy:
- Mild-to-moderate bipolar disorder: Lamotrigine or quetiapine monotherapy
- Severe bipolar disorder or history of psychosis: Lithium or combination of atypical antipsychotic + lamotrigine
- Bipolar I with high relapse risk: Lithium preferred given superior efficacy 1
Monitoring Requirements:
- Lithium levels monthly (increased renal clearance requires dose adjustments)
- Blood pressure checks (increased preeclampsia risk with some agents)
- Fetal growth monitoring
- Neonatal monitoring for withdrawal symptoms or poor adaptation 7
Critical Clinical Considerations
The Untreated Disease Risk
Discontinuing medication is often more dangerous than continuing treatment 5, 6. Untreated bipolar disorder in pregnancy causes:
- Poor prenatal care
- Decreased fetal growth
- Premature delivery
- Low birth weight
- Risky maternal behaviors during acute episodes 3
Women with bipolar disorder face extremely high postpartum relapse risk, but this risk is more than twofold lower with adequate pharmacological prophylaxis 1.
Common Prescribing Errors
A concerning pattern emerges from recent data: only 22.4% of pregnant women with documented bipolar disorder were on mood stabilizers at delivery, while 35.7% were inappropriately maintained on antidepressant monotherapy 6. Antidepressants as monotherapy increase the risk of mania and rapid cycling, especially in bipolar I, and are not recommended 6.
Postpartum Management
The postpartum period represents the highest risk time for relapse. A written perinatal bipolar relapse prevention plan should include 1:
- Maintenance treatment during pregnancy
- Medication immediately after delivery (often requires dose increase back to pre-pregnancy levels)
- Strategies to ensure adequate sleep and stable circadian rhythm
- Early recognition of relapse symptoms
- Feeding plan (breast vs. bottle)
Breastfeeding Considerations
- Lamotrigine and valproate: Safe during lactation 4
- Lithium: Requires monitoring of infant lithium levels and thyroid function
- Atypical antipsychotics: Generally compatible with breastfeeding, though infant monitoring recommended
Practical Implementation
For a newly pregnant patient on valproate: Immediately switch to lamotrigine (titrate up slowly to prevent rash) or start quetiapine for rapid stabilization while transitioning.
For a patient planning pregnancy on lithium: Continue lithium, optimize dose pre-conception, plan for monthly level monitoring, and arrange high-risk obstetric care.
For severe acute mania in pregnancy: Atypical antipsychotic (quetiapine or olanzapine) provides rapid stabilization with acceptable safety profile; add lithium if insufficient response 1.
The evidence strongly supports continuing pharmacological treatment throughout pregnancy rather than attempting medication-free pregnancy, as the maternal and fetal risks of untreated bipolar disorder substantially outweigh the relatively modest medication-related risks when appropriate agents are selected 1, 5, 3.